Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

1 week ago 1
Read Entire Article
  1. Homepage
  2. Finance
  3. Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Related

Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, died while leading campers to safety during the devastating floods

Richard ‘Dick’ Eastland, Camp Mystic’s 74-year-old owner, di...

51 minutes ago 0
Energy Department warns of more U.S. blackouts by 2030 from relying on renewables

Energy Department warns of more U.S. blackouts by 2030 from ...

1 hour ago 0
Oil futures flip higher as signs of strong demand outweigh larger OPEC+ output boost

Oil futures flip higher as signs of strong demand outweigh l...

2 hours ago 0
Exxon expects Q2 earnings hit from lower oil and gas prices

Exxon expects Q2 earnings hit from lower oil and gas prices

3 hours ago 0
Apple loses its top AI models executive to Meta’s hiring spree

Apple loses its top AI models executive to Meta’s hiring spr...

3 hours ago 1
Social Security sends incorrect email saying ‘Big Beautiful Bill’ ends taxes on benefits—here’s what is actually changing

Social Security sends incorrect email saying ‘Big Beautiful ...

3 hours ago 0
Vistra approved for 20-year operations extension at Ohio nuclear plant

Vistra approved for 20-year operations extension at Ohio nuc...

3 hours ago 0
‘Kids are the canaries in the coal mine’: Huge study finds worse childhood obesity, depression, all-around ill health

‘Kids are the canaries in the coal mine’: Huge study finds w...

4 hours ago 0
Gold finishes flat as stronger dollar offsets safe-haven demand

Gold finishes flat as stronger dollar offsets safe-haven dem...

4 hours ago 0
Aura to launch of U.S. public offering

Aura to launch of U.S. public offering

4 hours ago 0
xAI plans to release Grok 4 on Wednesday

xAI plans to release Grok 4 on Wednesday

4 hours ago 1
Penguin Solutions Q3 2025 Earnings Preview

Penguin Solutions Q3 2025 Earnings Preview

4 hours ago 0
Aehr Test Systems Q4 2025 Earnings Preview

Aehr Test Systems Q4 2025 Earnings Preview

4 hours ago 0
Saratoga Investment Q1 2026 Earnings Preview

Saratoga Investment Q1 2026 Earnings Preview

4 hours ago 1
Carnival corporation announces upsizing, pricing of $3B senior unsecured notes offering

Carnival corporation announces upsizing, pricing of $3B seni...

4 hours ago 0
Trump donor scammed out of $40k in crypto after someone pretending to be Steve Witkoff allegedly sent an eerily convincing email

Trump donor scammed out of $40k in crypto after someone pret...

4 hours ago 1
Enthusiast Gaming appoints Alex Macdonald as CEO, announces divestment

Enthusiast Gaming appoints Alex Macdonald as CEO, announces ...

4 hours ago 0
Volatus Aerospace delivers ~$1.8M in ISR drones to NATO country

Volatus Aerospace delivers ~$1.8M in ISR drones to NATO coun...

4 hours ago 0
Erie Indemnity resumes full insurance operations after cyber attack

Erie Indemnity resumes full insurance operations after cyber...

4 hours ago 0
Ceribell sues Natus Medical for patent infringement

Ceribell sues Natus Medical for patent infringement

4 hours ago 0

Trending

Popular

TechCrunch Mobility: The state of EV sales and Rivian secures the next $1B from VW

TechCrunch Mobility: The state of EV sales and Rivian secure...

3 days ago 6
Castelion raises $350M Series B to scale hypersonic missile business

Castelion raises $350M Series B to scale hypersonic missile ...

4 days ago 6
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© FBT Company 2025. All rights are reserved